Latest The New England Journal Stories
To prevent a common type of stroke, intensive medical therapy could be better by itself than in combination with surgery that props open affected arteries.
Anesthesiology researchers have shown that a device approved by the Food and Drug Administration to reduce the risk that patients will recall their surgery does not lower the risk of the problem, known as intraoperative awareness, any more than a less expensive method.
For asthma patients who continue to suffer from symptoms even after taking their inhaled steroids, a new drug called lebrikizumab may be a treatment option, and a simple blood test can determine the effectiveness of the drug.
BGI, the world's largest genomic organization in the world, today announced that the study on Genomic Analysis of Shiga Toxin-Producing Escherichia coli O104:H4, conducted by BGI and its collaborators, was published online today in The New England Journal of Medicine (NEJM).
Placebos are "dummy pills" often used in research trials to test new drug therapies and the "placebo effect" is the benefit patients receive from a treatment that has no active ingredients.
Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB.
An advanced imaging technique has revealed that some U.S. military personnel with mild blast-related traumatic brain injuries have abnormalities in the brain that have not been seen with other types of imaging.
"Have You Had the Talk?(TM)" Toolkit Facilitates End-of-Life Discussions for Physicians, Caretakers and Patients DETROIT, May 19, 2011 /PRNewswire-USNewswire/ -- The 2008 presidential campaign introduced a debate on an unexpected topic: physician/patient conversations on end-of life options.
A team led by researchers at National Jewish Health has discovered a new genetic variation that increases the risk of developing pulmonary fibrosis by 7 to 22 times.
NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClipÂ® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.
- a slit in a tire to drain away surface water and improve traction.